Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults

HIV Clinical Trials

Volumn 7, Issue 4, 2006, Pages 172-183

  Lim, Hyun J ^a   Okwera, Alphonse ^b   Mayanja Kizza, Harriet ^c   Ellner, Jerrold J ^d   Mugerwa, Roy D ^c   Whalen, Christopher C ^e,f  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Ugandan National Tuberculosis and Leprosy Programme   (Uganda)

^c MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Disease progression; HIV AIDS; Natural history; Prevention; Survival tuberculosis

Indexed keywords

ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CLONAL ANERGY; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FATALITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; UGANDA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; ISONIAZID; MALE; PROPORTIONAL HAZARDS MODELS; PYRAZINAMIDE; RIFAMPIN; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS; UGANDA;

EID: 33750850023     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0704-172     Document Type: Article

References (40)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human deficiency virus infection. N Engl J Med. 1998;338:853-856.
4. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
5. UNAIDS. Report on the global HIV/AIDS; epidemic, December 2004. Available at: http://www.usaids.org/publications/index.html. Accessed September 1, 2005.
6. The President's Emergency Plan for AIDS Relief - 5/27/03. Available at: http://www.usaid.gov/our_work/global_health/aids/pepfarfact.html. Accessed September 1, 2005.
7. Yeni PG, Hammer SM, Hirsch MS, Saag MS, et al. Treatment for Adult HIV infection. 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004; 292:251-365.
8. Nunn AJ, Kengeya-Keyondo JF, Malamba SS, Seeley JA, Moulder DW. Risk factors for HIV-1 infection in adults in a rural Ugandan community: a population study. AIDS. 1994;8:81-86.
9. Nunn AJ, Wagner HU, Okongo JM, Malamba SS, Kengeya-Keyondo JF, Moulder DW. HIV-1 infection in a Ugandan town on the trans African highway: prevalence and risk factors. Int J STD AIDS. 1996;7:123-130.
10. Morgan D, Maude GH, Malamba SS, et al. HIV-1 disease progression and AIDS-defining disorder in a rural Uganda cohort. Lancet. 1997;350:245-250.
11. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuberc Lung Dis. 1992;73:311-321.
12. Guelar A, Gatell JM, Verdejo J, at al. A prospective study of the risk of tuberculosis among HIV-Infected patients. AIDS. 1993;6:1435-1439.
13. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. New Engl J Med. 1997;337:801-808.
14. Johnson JL, Okwera A, Hom DL, Mayanja H, Kityo CM, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-Infected adults. AIDS. 2001;15:1-11.
15. World Health Organization. Acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV-1 infection and disease. Wekly Epidemiol Rec. 1990;65:221-228.
16. Tuner BJ, Markson LE, McKee L, et al. The AIDS-defining diagnosis and subsequent complications: a survival-based severity index. J Acquir Immune Defic Syndr. 1991;4:1059-1071.
17. Mocroft AJ, Johnson MA, Sabin CA, Lipman M, Elford J, et al. Staging system for clinical AIDS patients. Lancet. 1995;346:L12-17.
18. Hanson DL, Chu SY, Farizo KM, Ward JW, et al. Distribution of CD4 T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. Arch Inter Med. 1995;155:1537-1542.
19. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-Infected persons. J Acquir Immune Defic Syndr. 1991;4:770-776.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc B. 1972;74:187-220.
22. SAS Institute Inc. SAS/STAT software. Cary, NC: SAS Institute Inc.
23. Morgan D, Maude GH, Malamba SS, Okongo MJ, Wagner H-U, et al. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet. 1997;350:245-250.
24. Morgan D, Whitworth JAG. The natural history of HIV-1 infection in Africa. Nat Med. 2001;7:143-145.
25. Del Amo J, Petruckevitch A, Phillips AN, Johnson AM, Stephenson JM, et al. Spectrum of disease in Africans with AIDS in London. AIDS. 1996;10:1563-1569.
26. Del Amo J, Petruckevitch A, Phillips A, Johnson AM, Stephenson J, et al. Disease progression and survival in HIV-1 infected Africans in London. AIDS. 1998;12:1203-1209.
27. Morgan D, Malamba SS, Orem J, Mayanja B, Okongo M, Whitworth JAG. Survival by AIDS defining conditions in rural Uganda. Sex Transm Infect. 2000;76:193-197.
28. O'Dell MW, Lubeck, DP, O'Driscoll P, Matsuno S. Validity of the Karnofsky performance status in an HIV-infected sample. J Acquir Defic Syndr Human Retrovirus. 1995;1:350-357.
29. Wenzel T, Pindur G, Morsdorf S, Giacchi J. Influence of HIV-infection on the Karnofsky score and general social functioning in patients with hemophilia. Haemostasis. 1998;28:106-110.
30. Fantoni M, Izzi I, Borgo D, Forno D, et al. Inter-rater reliability of a modified Karnofsky scale of performance status for HIV-infected individuals. AIDS Patient Care STDS. 1999;13:23-28.
31. Pezzotti P, Phillips AN, Dorrucci M, et al. Category of exposure to HIV and age in progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. BMJ. 1996;313:583-586.
32. Touloumi G, Karafoulidou A, Gialeraki A, Katsarou O, Milona I, et al. Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion. J Acquir Defic Syndr Human Retrovirus. 1998;19:89-97.
33. Hawken MP, Meme HK, Elliot LC, et al. Isonizid preventive therapy for tuberculosis in HIV-infected adults: results of a randomized controlled trial. AIDS. 1997;11:875-882.
34. Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-Infected Zambian adults. AIDS. 2001;15:215-222.
35. Bucher HC, Griffith LE, Guyaft GH, at al. Isonizid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 1999;13:501-507.
36. Moreno S, Miralles P, Diaz MD, et al. Isoniazid preventive therapy in human immunodeficiency virus-infected person. Long-term effect on development of tuberculosis and survival. Arch Intern Med. 1997;157:1729-1734.
37. Pinho AMF, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patient in Brazil. AIDS. 2001; 15:2129-2135.
38. Pape JW, Jean SS, Ho JL, at al. Effect of Isonizid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:268-272.
39. Dolan MJ, Clerici M, Blaatt SP, et al. In vitro T cell function delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis. 1995;172:79-87.
40. Gordin FM, Hatigan PM, Klimas NG, et al. Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. J Infect Dis. 1994;169:893-897.